Thulium Laser and Growth Factors for Androgenetic Alopecia

Androgenetic alopecia (AGA) is a common cause of hair loss worldwide. It mainly affects the frontal and parietal regions of the scalp in up to 70 % of men and 40 % of women and has a significant negative psychological and emotional impact on those affected. Various therapies are currently approved for the treatment of AGA in men and women, including topical minoxidil, topical or systemic finasteride, platelet-rich plasma and hair transplantation. In addition to these pharmacological and surgical interventions, laser therapies including thulium laser with growth factors have gained popularity. Despite the clinical use of the thulium laser with growth factors in combination with LED phototherapy, there are only a few studies to date that have adequately investigated the objective and patient-side benefits of this therapy.

NCT Number	NCT07079657
Lead Sponsor	Universitätsklinikum Hamburg-Eppendorf
Conditions	Androgenetic Alopecia (AGA)
Enrollment	30 participants
Start Date	2023-12-01
Primary Completion	2025-09-01 (estimated)
Study Completion	2025-10-01 (estimated)
Updated on ClinicalTrials.gov	2025-07-23